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Objectives. The majority of post-thrombotic women
are barred from using oral contraceptives. We
evaluated this policy for its clinical relevance.
Design. A meta-analysis of controlled studies between
1960 and 1993.
Setting. A Medline Computer search, from 1966 to
1993, in multiple languages, with the following
Index terms: thrombosis, thrombopheblitis, vein,
venous, pulmonary embolism, contraceptives, oestro-
gen, oral.
Study selection. A total of 588 articles or abstracts
were reviewed for controlled studies, in which an
index group was compared with a control group.
Included were one randomized trial, six follow-up
studies and eight case-control studies.
Main outcome measures. Summary thrombosis risk
for oral contraceptive users, number needed to
discontinue oral contraceptives to prevent one
(recurrent) thrombosis, comparison of additional
unwanted pregnancies and postpartum thrombosis
between alternative birth-control methods.
Results. The studies proved highly heterogeneous
with regard to size and direction of the risk estimate.
The summary relative risk of first thrombosis during
oral contraceptive use was 2.9 (95% CI, 0.5-17).
Since the risk of thrombosis recurrence is not well
known, we estimated alternatives, making various
hypothetical assumptions, wherein women would
continue to take oral contraceptives after a first
episode of thrombosis, or stop and switch to use of an
intra-uterine device, condom or the progestogen-
only pill. Depending on the assumptions with regard
to recurrence risk and the existence of possible
subgroups with genetic coagulation defects, the cost-
benefit ratio of advising against the use of oral
contraceptives after a first thrombosis varied tremen-
dously.
Conclusions. Our analysis shows that we lack the
necessary data for recurrence risk of venous throm-
bosis during continuing use of oral contraceptives, or
after switching to other modes of contraception. This
reflects the clinical uncertainties that result in highly
contradictory advice to young women who have
experienced a first thrombosis. Only follow-up studies
on recurrence risk will settle the issue.
Keywords: benefit-risk ratio, meta-analysis, oral
contraceptives, venous thrombosis.
Introduction
Since the first report on the occurrence of pulmonary
embolism in a young woman who used a combined
oral contraceptive (the oestrogen mestranol and the
progestogen norethynodrel) was published in 1961
[1], many studies on the relationship between oral
contraceptive use and venous thromboembolism
have been reported. Concern about recurrent venous
thrombosis caused many physicians to advise women
to cease use of oral contraceptives after a first
thrombotic episode. This implies that the woman
involved is forever barred from using oral contra-
ceptives. This policy has major consequences, and
should be evaluated for its clinical relevance, i.e. its
absolute effect and benefit-risk ratio. Two issues will
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be considered here. First, the size of the absolute risk
and the effect of advice against the use of oral
contraceptives: how many women should discon-
tinue oral contraceptive use in order to prevent one
thrombosis? Secondly, since oral contraceptives are
the most reliable, easily reversible method of con-
traception, the risk of alternative methods should be
taken into account. These alternative methods will
result in more pregnancies and undoubtedly more
pregnancy terminations, äs well äs puerperia, which
in itself increases the risk of deep vein thrombosis.
Therefore, the eure may be worse than the ailment.
In this meta-analysis we have attempted to quantify
all these aspects, in order to reach conclusions that
may assist the clinician in rational decision-making.
Given that the recurrence risk of thrombosis is not
well known, we must rely on a sensitivity analysis
that tests various hypothetical risks.
Methods
Data collection and deflnitions
We searched for studies, published in English, French
or German, in which the risk of venous thrombosis
for women who used oral contraceptives äs a method
of birth control had been estimated. The studies were
identified by using a computerized literature search
(Medline (l January 1966 to 31 December 1993),
with the following index terms: thrombosis, throm-
bopheblitis, vein, venous, pulmonary embolism,
contraceptives, oestrogen, oral), and by cross-
referencing. A first selection was made on the basis
of the abstracts, after which the entire manuscripts
were reviewed. The analysis in this report is limited
to controlled studies, in which an index group is
compared to a control group. Excluded were case
series and studies controlled by general popula-
tion data, and reports in which data for venous
thrombosis could not be differentiated from data
for arterial thrombosis. In some reports, parts of
the data were published more than once. From these
articles we selected only those reporting the original
or final results. Overall data on venous thrombotic
events which also included flgures for rarely
occurring (neurological, ophthalmic or mesenteric)
thromboses were included.
Study characteristics, such äs type of study,
oestrogen dose, and use of objective methods to
diagnose venous thromboembolism, were indepen-
dently scored by two authors. In the event of
disagreement, the other two authors were consulted,
and a consensus could be reached in all cases.
Number needed to discontinue oral contraceptive use
Whereas a relative risk (RR) is useful for establishing
a causal association, it provides little Information
about the clinical relevance, which is dependent on
the absolute risk, i.e. the probability for an individual
patient. From the absolute risk one may, by simple
calculation, estimate the number of women that
should discontinue the use of oral contraceptives in
order to avoid one thromboembolic event [2]. Ob-
viously, if a drug increases the risk from 1/1000 to
10/1000 (risk difference 9/1000), a total of 1000/9
(1/risk difference) = 111 women should discontinue
this drug in order to avoid one thromboembolic
event.
To perform this analysis, we need to estimate the
incidence of thrombosis in those women who use
oral contraceptives, and in those who do not use
them. First, we estimated the Overall incidence (I) of
venous thrombosis in women of child-bearing age,
by dividing the number of first, objectively confirmed
episodes of deep vein thrombosis in 15- to 44-year-
old women over a 5-year period (data from the
Leiden Thrombophilia Study (LETS) [3]) by the total
number of women-years of this age group in the
same well-defined greater Leiden area. The incidence
of thrombosis among oral contraceptive users (Ie)
and non-users (I0) can be estimated from this overall
incidence (I) by the following equation:
(Proportion of pill-users χ pooled relative risk χ Ι0)
+ (proportion non-users χ I0) = I.
I
e
 can be determined by multiplying I0 by the
pooled risk estimate. Age-specific data for oral con-
traceptive use for women aged 15 to 44 years were
obtained from the Dutch Central Bureau of Statistics
[4]·
In order to obtain more Information about the risk-
benefit ratio with regard to unwanted pregnancies or
post-partum thrombosis, we hypothetically com-
pared the number of expected birth control failures
and recurrent thrombotic episodes in three cohorts of
100000 post-thrombotic women, each using oral
contraceptives or alternative birth-control methods
for l year. The thrombosis frequency during preg-
nancy or during the post-partum period was esti-
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mated to be l per 100 women [5]. The failure rate
(accidental pregnancy risk) among typical couples
('daily life') was considered to be 3 per 100 user
years for oral contraceptives, 3 per 100 user years for
intra-uterine devices, and 12 per 100 user years for
condom use [6]. We took the lowest expected failure
rates among couples who use the method perfectly to
be 0.1 per 100 user years for oral contraceptives, 0.8
per 100 user years for intra-uterine devices, 2 per
100 user years for condom use, and 0.5 per 100 user
years for the progestogen-only pill [6].
Staüsücal analysis
Prior to pooling, we tested for homogeneity between
the studies analysed, i.e. we tested the hypothesis
that the differences between the reported risks were
only due to random error around the 'true' RR [7].
The test-statistic was computed by calculating G =
Σwl(k-l~~kt,)z, in which wt is defined äs the inverse
squared Standard error of the natural logarithm of
the relative risks, /q is the estimate of the log relative
risk of each study, and ke is the pooled estimate of the
log relative risk. Under the null hypothesis, G follows
a Chi-square distribution with n — l degrees of
freedom (df) for n studies. Despite the reported
insensitivity of this test, the studies still proved highly
heterogeneous (G = 80.3, P < 0.001; df 14). There-
fore, the pooled estimate was estimated äs the
unweighted average of natural logarithmic trans-
formed point estimates, whereas the Standard de-
viation was calculated in the Standard manner for n
(number of studies) observations.
For each study the relative risks with their 95%
confidence intervals (CI) were extracted or recalcu-
lated, if necessary. In some articles only stratum-
specific relative risks were given. Whenever two-by-
two tables were provided, the outcomes within these
studies were combined by the Mantel-Haenszel
method. Otherwise, the natural logarithm of the
reported risks was recalculated to one relative risk by
using inverse variance weights. In order to estimate
whether publication bias existed, a funnel plot was
constructed [8].
Results
A total of 588 papers and abstracts were examined
for possible inclusion in the study. We reviewed 206
studies in detail and identified 18 controlled studies.
Three of these were excluded: in two studies only the
risk of fatal pulmonary embolism was investigated,
which did not fall within the scope of our study
[9, 10] and in another study the controls were
women with suspected pulmonary embolism that
could not be confirmed by objective tests and, more
significantly, an appropriate age-matched control
group for women who used oestrogens for birth
control only (and not for post-menopausal hormone
replacement) could not be obtained from that study
[11]. The general results of two of these excluded
papers showed the absence of a relationship between
(fatal) thrombosis and the use of oral contraceptives
[10, 11]. The 15 remaining studies consisted of eight
case-control studies [12-19], six follow-up studies
[20-25] and one randomized clinical trial [26].
Figure l shows the reported relative risks with 95%
confidence intervals. It clearly illustrates that the
results differ substantially in direction and effect. The
unweighted summary relative risk was 2.9 (95% CI,
0.5-17). On average, the reported risks were higher
in case-control studies (RR 4.2; 95% CI, 1.3-14)
than in follow-up studies (RR 2.1; 95% CI, 0.3-16).
The randomized clinical trial yielded no increase in
thrombosis risk for oral contraceptive users (RR 1.1;
95% CI, 0.4-2.9).
In these studies, objective diagnostic methods were
either not explored at all, or were only explored in
some of the patients. In none of the studies was
objective testing performed in more than 90% of
diagnoses. Four studies included data for oral contra-
ceptives containing less than 50 μg oestrogen per pill
[18, 23-25], and in only one was a ' dose-response'
relationship between the amount of oestrogen and
thrombosis risk present [25]. However, the majority
of the patients in these studies were using oral
contraceptives containing ^ 50 μg oestrogen. Five
studies reported the use of oral contraceptives con-
taining ^ 50 μg [17, 20-22, 26], and in six studies
the dosages were not stated [12-16, 19].
The total number of women aged 15 to 44 years in
the greater Leiden area was assessed to be 99018
(on the basis of data from the municipal authorities).
During the 5-year period (1988-1992) of the LETS
study we observed 101 female patients between 15
and 44 years of age with a first, objectively confirmed
venous thrombotic event. Therefore, the overall
incidence (I) was 2/10000. In total, 41708 (42%)
women aged 15-44 years may be expected to use
oral contraceptives. Substituting these values into the
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Fig. l Funnel plot of the relative risks and 95% confidence intervals ranked by Standard error. FUP denotes follow-up study, CC
denotes case-control study and RCT denotes randomized clinical trial. (A) represents the pooled unweighted relative risk; (B) represents
the classical precision weighted (using inverse variance weights) pooled relative risk.
equation, we obtain (0.42 χ 2.9 χ Ι0) + (0.58 χ Ι0) =
2/10000. Therefore, the incidence for non-oral
contraceptive users was calculated to be 1.1 per
10000, and the incidence for oral contraceptive
users was calculated to be 3.3 per 10000. If oral
contraceptive use increases the risk of venous throm-
bosis from 1.1 to 3.3 per 10000 (risk difference
2.2/10000), a total of 4545 asymptomatic women
should refrain from using oral contraceptives in
order to prevent a first episode of deep vein thrombosis
within l year. At present, the recurrent risk of
venous thrombosis, after a woman has stopped using
oral contraceptives because of this thrombosis, is not
known. It might be higher than the baseline risk,
since these women might have other risk factors, but
it must be lower than the primary risk during oral
contraceptive use, since an important risk factor has
been removed. Therefore, we have tentatively used a
relative risk of two for recurrent thrombosis in
women who have stopped taking oral contraceptives.
Consequently, their risk of thrombosis recurrence is
2.2/10000 (the additional recurrence risk is there-
fore 1.1/10000). Equally unknown is the recurrence
risk when women continue to use oral contraceptives
after their thrombotic episode. It will be at least äs
high äs the primary risk, and may be higher if there
are women who are particularly sensitive to the
thrombogenic effect of oral contraceptives. By way of
sensitivity analysis we have set absolute risks of
thrombosis recurrence at 4.4/10000 (primary risk
for oral contraceptive users (3.3/10000) +
additional recurrence risk of 1.1/10000),
9.9/10000 and 33/10000 (representing relative
risks of 3 and 10, i.e. complementary to the risk of
other factors). The latter risks may appear to be high.
However, they approach the risks that are observed
in subgroups with genetic coagulation deficiencies
[27, 28]. On the basis of these absolute risks, 4545,
1299 or 325 women, respectively, should discon-
tinue the use of oral contraceptives in order to avoid
one second thrombotic episode per year.
Table l lists the outcome with regard to preg-
nancies and thrombosis in five hypothetical cohorts
of 100000 post-thrombotic women monitored for l
year. The results are highly variable, not only with
regard to assumptions about recurrence rate, but
also with regard to assumptions about contraceptive
failures. Under all but the highest assumption for
]995 Blackwell Science Ltd Journal of Internet] Mediane 238: 31-37
ORAL C O N T R A C E P T I V E S AND V E N O U S THROMBOEMBOLISM 35
Table l Companson of thrombosis outcome m three cohorts of post-thiombotic women
Incidencc of recuirent VT.]:
Cases of VT
Failure rate
Unwanted pregnancies
Frequency of VT dunng
pregnancy and puerpenum
Additional cases of VT§
Totdl number of VT
Oral contraceptive
(lOOOOOpyt)
44/10000
44
003(0001*)
3000 (100*)
001
30(1*)
74(45*)
Intra-utenne device Condom
(100000 py) (100000 py)
9 9/10000
99
003 (0001*)
3000 (100*)
001
30(1*)
129 (100)
33/10000
330
0 03 (0 001*)
3000(100*)
001
30(1*)
360(331*)
2 2/10000
22
0 03 (0 008*)
3000 (800*)
001
30(8*)
52 (30*)
2 2/10000
22
012(002*)
12000(2000*)
001
120 (20*)
142 (42*)
*Data when the lowest expected failure lates were apphed
fpy, person years
i VT, venous thrombosis.
§ Calculated by: (number of pregnancies) χ (thrombosis risk, pregnancy and puerpenum)
recurrence risk, among typical couples ('daily life')
the number of unexpected pregnancies äs well äs the
sum of venous thrombotic episodes will be highest
among condom users. The use of intra-uterine
devices will result in a reduction of at least 30% in
the number of venous thrombotic episodes, and in an
equal number of accidental pregnancies when com-
pared to use of oral contraceptives. When we apply
the lowest expected failure rates ('perfect use'), both
intra-uterine device and condom use lead to a
decrease in thrombosis outcome. However, this
reduction in thrombosis will be accompanied by an
8- to 20-fold increase in unwanted pregnancies,
because intra-uterine devices and condoms have
higher failure rates than oral contraceptives, even
when the methods are used perfectly.
Discussion
The results of this overview suggest that oral
contraceptives are associated with an almost three-
fold increase in risk of venous thrombosis. Given the
low absolute thrombosis risk in 15- to 44-year-old
women, the effort that must be made to prevent
recurrent thrombosis is highly dependent on assump-
tions about recurrence risk and contraceptive failure
rates.
The selected studies were not homogeneous, i.e.
the results showed more Variation around the
summary estimate than could be explained by chance
alone. The studies are therefore difficult to Interpret
äs a whole. The pooled summary estimate of case-
control studies (RR 4.2) was higher than the pooled
summary estimate of follow-up studies (RR 2.1). In
both study designs, biases may explain at least some
of the results, äs was nicely illustrated by Katerndahl
et al. [29]. Interestingly, in the only randomized
controlled trial, which will not have suffered from the
biases described above, no difference was found in
thrombosis risk between 4965 oral contraceptive
users (aged 15 to 40 years) and a group of 4933
control women who were using vaginal barrier
methods (RR 1.1; 95% CI, 0.4-2.9) [26].
Publication bias, caused by under-reporting
smaller studies with no significant effect, must
always be considered äs a possible explanation of the
outcome in a critical review. However, ' funnel plot'
analysis of the distribution of the various study
outcomes ranked by their Standard errors did not
suggest that such a bias was present (Fig. 1) [30].
The 'true' underlying thrombotic risk also varies
according to the type of oral contraceptive used. The
overall results of the 15 studies were dealing with
higher-dose oestrogen-containing pills, which appear
to be associated with a higher thrombosis risk than
currently marketed 'sub-fifty' formulations [31-34],
Furthermore, women with leg Symptoms who are
using oral contraceptives are more likely to be
diagnosed äs having venous thrombosis than women
with the same leg Symptoms who are not current
users of oral contraceptives. This detection and
referral bias will result in an overestimation of the
relative risk, the more so since, in the studies selected,
for many patients the diagnosis was not confirmed by
means of an objective test, which will without doubt
have resulted in numerous false-positive diagnoses
[35, 36], especially for women using oral contra-
ceptives [37].
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The use of condoms of intra-uterine devices äs an
alternative to oral contraceptives will lead to more
unwanted pregnancies. Under the lowest assump-
tions for thrombosis risk among typical couples this
might give an increase in the occurrence of venous
thrombosis (Table 1). The decision of whether to
continue using oral contraceptives after a thrombotic
event or to switch to an intra-uterine device or
progestagen-only puls is a more difficult one. The risk
of thrombosis is decreased, but the risk of unwanted
pregnancies can be increased considerably compared
to that associated with oral contraceptive use,
dependmg on which efficacy criterion is used.
The data are based on the total number of women
with a first thrombosis. For specific subgroups, i.e.
those with genetic coagulation disorders, the risk will
be higher. Evidence supporting this view is already
available for deficiencies of protein C, protein S and
antithrombin [38]. However, these genetic risk
factors have a very low prevalence in the general
population, and hitherto played only a minor role in
considerations when advising women who had
experienced a first thrombosis during oral contra-
ceptive use. However, this Situation might change
completely with the recent discovery of genetic
resistance to activated protein C, which is present in
3% of the general population and in 20% of
unselected consecutive thrombosis patients [39]. It
leads to a sevenfold increase in thrombosis risk,
which might be further enhanced by oral con-
traceptive use [27-28]. For these women, who
represent a significant proportion of young women
with deep venous thrombosis, future follow-up
studies will describe the magnitude of the recurrent
risk. Even so, in all of these women with genetic
coagulation disorders, the consequences of prescrib-
ing less reliable birth-control methods should be
carefully considered, given the additionally increased
percentages of pregnancy- and post-partum throm-
bosis [40].
Our attempt to quantify the difficult clinical
decision of whether or not to discontinue the use of
oral contraceptives after a first thrombosis has led to
the startling realization that we lack the necessary
data. Depending on the assumptions made, one can
arrive at totally opposite conclusions. This appears to
be a reflection of the uncertainties that exist in
current clinical practice, where highly contradictory
advice is given to young women. In the end, the
relative subjective fears of either thrombosis or
pregnancy, and the relative acceptability of different
forms of contraception for a woman and her partner,
might be the decisive factors.
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